Identification of cryptic nuclear localization signals in the prion protein

Abnormal transport of C-terminally truncated prion protein (PrP) to the nucleus has been reported in cell models of familial prion disorders associated with a stop codon mutation at residues 145 or 160 of the PrP. In both cases, PrP is translocated to the nucleus in an energy-dependent fashion, implying the presence of cryptic nuclear localization signal(s) in this region of PrP. In this report, we describe the presence of two independent nuclear localization signals (NLS) in the N-terminal domain of PrP that differ in the efficiency of nuclear targeting. When acting independently, each NLS sequence mediates the transport of tagged bovine serum albumin into the nucleus of permeabilized cells. When acting together, the two NLS sequences complement each other in transporting the N-terminal fragment of PrP to the nucleus of transfected cells, where it accumulates at steady state. Interestingly, nuclear translocation of PrP is blocked completely if the N-terminal fragment is extended to include one or two N-glycans. The glycosylated PrP fragment, instead, accumulates in the endoplasmic reticulum. Extension of the N-terminal fragment to include both N-glycans and the glycosyl phosphatidylinositol anchor, as expected, directs PrP to the plasma membrane. These observations hold implications for the pathogenesis of familial prion disorders, where truncated and abnormally glycosylated mutant PrP forms may accumulate in the nucleus and initiate neurotoxicity through novel mechanisms.

[1]  H. Budka,et al.  Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Ikonen,et al.  Basolateral protein transport in streptolysin O-permeabilized MDCK cells , 1994, The Journal of cell biology.

[3]  F. Cohen,et al.  Prion diseases of humans and animals , 1996 .

[4]  S. Ferrari,et al.  Proteasomal Degradation and N-terminal Protease Resistance of the Codon 145 Mutant Prion Protein* , 1999, The Journal of Biological Chemistry.

[5]  William D. Richardson,et al.  A short amino acid sequence able to specify nuclear location , 1984, Cell.

[6]  S. Prusiner,et al.  Amyloid protein of Gerstmann‐Sträussler‐Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N‐terminal glycine at codon 58. , 1991, The EMBO journal.

[7]  D. Harris,et al.  A Mutant Prion Protein Displays an Aberrant Membrane Association When Expressed in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[8]  D. Dormont,et al.  Search for a Nuclear Localization Signal in the Prion Protein , 1998, Molecular and Cellular Neuroscience.

[9]  D. Harris,et al.  Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Harris,et al.  Mutant and Infectious Prion Proteins Display Common Biochemical Properties in Cultured Cells (*) , 1996, The Journal of Biological Chemistry.

[11]  S. Adam,et al.  Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors , 1990, The Journal of cell biology.

[12]  C. Weissmann,et al.  Molecular Genetics of Transmissible Spongiform Encephalopathies* , 1999, The Journal of Biological Chemistry.

[13]  Albert Taraboulos,et al.  Proteasomes and ubiquitin are involved in the turnover of the wild‐type prion protein , 2001, The EMBO journal.

[14]  A. Negro,et al.  The Metabolism and Imaging in Live Cells of the Bovine Prion Protein in Its Native Form or Carrying Single Amino Acid Substitutions , 2001, Molecular and Cellular Neuroscience.

[15]  B. Ghetti,et al.  Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Lee,et al.  Internalization of mammalian fluorescent cellular prion protein and N‐terminal deletion mutants in living cells , 2001, Journal of neurochemistry.

[17]  J. Collinge Prion diseases of humans and animals: their causes and molecular basis. , 2001, Annual review of neuroscience.

[18]  K Wüthrich,et al.  NMR characterization of the full‐length recombinant murine prion protein, mPrP(23–231) , 1997, FEBS letters.

[19]  B. Ghetti,et al.  Prion Protein Amyloidosis , 1996, Brain pathology.

[20]  D. Harris,et al.  Prion Diseases: What Is the Neurotoxic Molecule? , 2001, Neurobiology of Disease.

[21]  Neena Singh,et al.  Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. , 2003, Journal of Alzheimer's disease : JAD.

[22]  B. Ghetti,et al.  A 7-kDa Prion Protein (PrP) Fragment, an Integral Component of the PrP Region Required for Infectivity, Is the Major Amyloid Protein in Gerstmann-Sträussler-Scheinker Disease A117V* , 2001, The Journal of Biological Chemistry.

[23]  P E Wright,et al.  Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Shu G. Chen,et al.  Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation* , 1997, The Journal of Biological Chemistry.

[25]  R. Sternglanz,et al.  PNG1, a Yeast Gene Encoding a Highly Conserved Peptide:N-Glycanase , 2000, The Journal of cell biology.

[26]  G. Dreyfuss,et al.  Transport of Proteins and RNAs in and out of the Nucleus , 1999, Cell.

[27]  R. Fletterick,et al.  Predicted secondary structure and membrane topology of the scrapie prion protein. , 1987, Protein engineering.

[28]  S. Lindquist,et al.  De novo generation of a PrPSc-like conformation in living cells , 1999, Nature Cell Biology.

[29]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[30]  M. Bachmann,et al.  Kinetics of expression of prion protein in uninfected and scrapie‐infected N2a mouse neuroblastoma cells , 1993, Cell biochemistry and function.

[31]  H. Kretzschmar,et al.  Cellular Phenotyping of Secretory and Nuclear Prion Proteins Associated with Inherited Prion Diseases* , 2002, The Journal of Biological Chemistry.

[32]  S. Lindquist,et al.  Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Neena Singh,et al.  Prion Peptide 106–126 Modulates the Aggregation of Cellular Prion Protein and Induces the Synthesis of Potentially Neurotoxic Transmembrane PrP* , 2002, The Journal of Biological Chemistry.

[34]  Arunandan Kumar,et al.  The Chaperone Protein BiP Binds to a Mutant Prion Protein and Mediates Its Degradation by the Proteasome* , 2000, The Journal of Biological Chemistry.

[35]  Terrance T. Kummer,et al.  Mutant Prion Proteins Are Partially Retained in the Endoplasmic Reticulum* , 2001, The Journal of Biological Chemistry.